A startup pharmaceuticals company wants to capitalize on the backlash against high drug prices by developing slightly different versions of expensive brand-name drugs and selling them at a significantly lower price than competitors. The new company, EQRx Inc., aims to bring 10 drugs to market over the next decade and sell them for perhaps as little as one-third to one-fifth of rivals’ prices, the company’s Co-Founder and Chief Executive Alexis Borisy said.

Source: Wall Street Journal January 12, 2020 15:11 UTC